Blueprint Medicines (BPMC) PT Raised to $102 at Wedbush, Following Trial Data Release

September 22, 2020 2:09 PM EDT
Get Alerts BPMC Hot Sheet
Price: $89.68 +3.09%

Rating Summary:
    13 Buy, 6 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 22 | Down: 26 | New: 45
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Wedbush analyst David Nierengarten raised the price target on Blueprint Medicines (NASDAQ: BPMC) to $102.00 (from $100.00) while maintaining a Outperform rating.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst PT Change